Key result
Chronic sildenafil treatment initiated 3 days post-myocardial infarction preserved fractional shortening and significantly reduced myocardial fibrosis to 5.8% compared to 18.9% with saline at 28 days.
Why the study?
Does sildenafil improve left ventricular function and remodeling in a mouse model of post-myocardial infarction heart failure?
Does sildenafil improve left ventricular function and remodeling in a mouse model of post-myocardial infarction heart failure?
Delayed chronic sildenafil treatment initiated 3 days post-myocardial infarction attenuates left ventricular dysfunction and adverse remodeling in mice via inhibition of the RhoA/Rho-kinase pathway.
Answers are grounded in this paper and cite their sources.
Sildenafil initiated 3 days post-MI attenuates HF progression in mice; extends immediate-treatment data and supports RhoA/Rho-kinase as a therapeutic target for further study.
Chronic inhibition of phosphodiesterase-5 with sildenafil immediately after permanent occlusion of the left anterior descending coronary artery was shown to limit ischemic heart failure (HF) in mice. To mimic a more clinical scenario, we postulated that treatment with sildenafil beginning at 3 days post-myocardial infarction (MI) would also reduce HF progression through the inhibition of the RhoA/Rho-kinase pathway. Adult male ICR mice with fractional shortening < 25% at day 3 following permanent left anterior descending coronary artery ligation were continuously treated with either saline (volume matched, ip, 2 times/day) or sildenafil (21 mg/kg, ip, 2 times/day) for 25 days. Echocardiography showed fractional shortening preservation and less left ventricular end-diastolic dilatation with sildenafil treatment compared with saline treatment at 7 and 28 days post-MI (P < 0.05). Both fibrosis and apoptosis, determined by Masson's trichrome and terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling (TUNEL), respectively, were attenuated in the sildenafil-treated mice (P < 0.05 vs. saline). Western blot analysis showed enchanced Bcl-2-to-Bax ratio with sildenafil treatment (P < 0.05 vs. saline). Activity assay showed sildenafil-mediated PKG activation 1 day after treatment (P < 0.05 vs. sham and saline). PKG activation was associated with sildenafil-mediated inhibition of Rho kinase (P < 0.05) compared with saline treatment, whereas PKG inhibition with KT-5823 abolished this inhibitory effect of sildenafil. In conclusion, for the first time, our findings show that chronic sildenafil treatment, initiated at 3 days post-MI, attenuates left ventricular dysfunction independent of its infarct-sparing effect, and this cardioprotection involves the inhibition of the RhoA/Rho-kinase pathway. Sildenafil may be a promising therapeutic tool for advanced HF in patients.
No takes yet. Share an insight, caveat, or question.
Chau et al. (2011) studied Heart failure post-myocardial infarction (n=113). Sildenafil vs. Saline (volume matched, ip, 2 times/day) was evaluated on Fractional shortening at 7 and 28 days post-MI (p=<0.05). Chronic sildenafil treatment initiated 3 days post-myocardial infarction preserved fractional shortening and significantly reduced myocardial fibrosis to 5.8% compared to 18.9% with saline at 28 days.
Synapse has enriched 10 related papers. Consider them for comparative context: